Best Practice & Research Clinical Haematology
Volume 22, Issue 1 , Pages 3-8 , March 2009

Thrombosis and cancer: Trousseau syndrome revisited

References 

  1. Trousseau A. 2nd edn. Phlegmasia Alba Dolens. Clinique Médicale de l'Hçtel Dieu de Paris. vol 3. Paris: JB Baillère; 1865;p. 659–12
  2. Billroth T. Lectures on surgical pathology and therapeutics:a handbook for students and practitioners. 8th edn. London: The New Sydenham Society; 1878;p. 1877–78
  3. Cliffton EE, Grossi CE. Fibrinolytic activity of human tumors as measured by the fibrin-plate method. Cancer. 1955;8:1146–1154
  4. Grossi CE, Agostino D, Cliffton EE. The effect of human fibrinolysin on pulmonary metastases of Walker 256 carcinoma. Cancer Res. 1960;20:605–608
  5. Agostino D, Grossi CE, Cliffton EE. Effect of heparin on circulating Walker carcinosarcoma 256 cells. J Natl Cancer Inst. 1961;5:463–473
  6. Cliffton EE, Agostino D. Factors affecting the development of metastatic cancer. Effect of alterations in clotting mechanism. Cancer. 1962;15:276–283
  7. Donati MB. Thrombosis and cancer; a personal view. Thromb Haemost. 2007;98:126–128
  8. Dolfini E, Azzarone B, Pedulla D, et al. Characterization of human fibroblasts from cancer patients: loss of fibrin clot retractile activity after ‘in vitro’ spontaneous transformation. Eur J Cancer. 1976;12:823–825
  9. Donati MB, Dolfini E, Morasca L, et al. Fibrin clot retraction by a rat rhabdomyosarcoma cell line. Thromb Res. 1976;8:707–711
  10. Curatolo L, Colucci M, Cambini AL, et al. Evidence that cells from experimental tumours can activate coagulation factor X. Br J Cancer. 1979;40:228–233
  11. Poggi A, Polentarutti N, Donati MB, et al. Blood coagulation changes in mice bearing Lewis lung carcinoma, a metastasizing tumor. Cancer Res. 1977;37:272–277
  12. Chmielewska J, Poggi A, Mussoni L, et al. Blood coagulation changes in JW sarcoma, a new metastasizing tumour in mice. Eur J Cancer. 1980;16:1399–1407
  13. Mussoni L, Poggi A, de Gaetano G, et al. Effect of ditazole, an inhibitor of platelet aggregation, on a metastasizing tumour in mice. Br J Cancer. 1978;37:126–129
  14. Poggi A, Mussoni L, Kornblihtt L, et al. Warfarin enantiomers, anticoagulation, and experimental tumor metastasis. Lancet. 1978;1:163–164
  15. Chmielewska J, Poggi A, Janik P, et al. Effect of defibrination with batroxobin on growth and metastasis of JW sarcoma in mice. Eur J Cancer. 1980;16:919–923
  16. Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: a factor X-activating procoagulant from malignant tissue. Thromb Res. 1975;6:127–137
  17. Colucci M, Delaini F, De Bellis Vitti G, et al. Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency. Biochem Pharmacol. 1983;32:1689–1691
  18. Lorenzet R, Bottazzi B, Locati D, et al. Failure of warfarin to affect the tissue factor activity and the metastatic potential of murine fibrosarcoma cells. Eur J Cancer Clin Oncol. 1985;21:263–265
  19. Donati MB, Gambacorti P, Casali B, et al. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res. 1986;46:6471–6474
  20. Grignani G, Falanga A, Pacchiarini L, et al. Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties. Int J Cancer. 1988;42:554–557
  21. Falanga A, Alessio MG, Donati MB, et al. A new procoagulant in acute leukemia. Blood. 1988;71:870–875
  22. Donati MB, Falanga A, Consonni R, et al. Cancer procoagulant in acute non lymphoid leukemia: relationship of enzyme detection to disease activity. Thromb Haemost. 1990;64:11–16
  23. Falanga A, Iacoviello L, Evangelista V, et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood. 1995;86:1072–1081
  24. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry. 1985;24:5558–5567
  25. Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukaemia. Blood. 1998;91:3093–3102
  26. Roncaglioni MC, D'Alessandro AP, Casali B, et al. Gamma-glutamyl carboxylase activity in experimental tumor tissues: a biochemical basis for vitamin K dependence of cancer procoagulant. Haemostasis. 1986;16:295–299
  27. Lorenzet R, Peri G, Locati D, et al. Generation of procoagulant activity by mononuclear phagocytes: a possible mechanism contributing to blood clotting activation within malignant tissues. Blood. 1983;62:271–273
  28. Rambaldi A, Alessio G, Casali B, et al. Induction of monocyte-macrophage procoagulant activity by transformed cell lines. J Immunol. 1986;136:3848–3855
  29. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436–444
  30. Falanga A, Brenner B, Rickles F. Fourth Intern.Conf. on Thromb.and Hemost. Issues in Cancer, Bergamo, Italy. Thromb Res. 2007;120(Suppl. 2):
  31. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318:404–407
  32. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343:886–889
  33. Barbui T, Falanga A. Thalidomide and thrombosis in multiple myeloma. J Thromb Haemost. 2003;3:421–422
  34. Prandoni P, Lensing AW, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327:1128–1133
  35. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6:401–410
  36. Carrier M, LeGal G, Wells PS, et al. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism?. Ann Int Med. 2008;149:323–333
  37. Zacharski LR, Donati MB. Registry of clinical trials of antithrombotic drugs in cancer. The Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Subcommittee on Hemostasis and Malignancy. Thromb Haemost. 1989;61:526–528
  38. Zacharski LR, Donati MB, Rickles FR. Registry of clinical trials of antithrombotic drugs in cancer: Second report. Thromb Haemost. 1993;70:357–360
  39. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction:ISIS-2.ISIS-2 (Second International Study of Infarct Survival). Collaborative Group. Lancet. 1988;2:349–360
  40. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardio. Lancet. 1990;336:65–71
  41. Donati MB, Poggi A. Malignancy and haemostasis. Br J Haematol. 1980;44:173–182
  42. Poggi A, Donati MB, Garattini S. Fibrin and cancer cell growth: problems in the evaluation of experimental models. In: Malignancy and the hemostatic system. New York: Raven Press; 1981;p. 89–101
  43. Bani MR, Falanga A, Alessio MG, et al. Blood coagulation changes in nude mice bearing human colon carcinomas. Int J Cancer. 1992;50:75–79
  44. Falanga A. The effect of anticoagulant drugs on cancer. J Thromb Haemost. 2004;2:1263–1265
  45. Lee AY, Levine MN, Baker RI, et al. Low-molecular- weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153
  46. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004;2:1266–1271
  47. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin therapy with dalteparin and survival in advanced cancer: the framing advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22:1944–1948
  48. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23:2130–2135
  49. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23:2123–2129
  50. Maugeri N, de Gaetano G, Barbanti M, et al. Prevention of platelet-polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, a low molecular weight heparins. Haematologica. 2005;90:815–821
  51. Maugeri N, Di Fabio G, Barbanti M, et al. Parnaparin, a low molecular weight heparin, prevents P-selectin- dependent formation of platelet- leukocyte aggregates in human whole blood. Thromb Haemost. 2007;97:965–973
  52. Lorenzet R, Donati MB. Blood clotting activation, angiogenesis and tumor metastasis: any role for TFPI?. Thromb Haemost. 2002;87:928–929
  53. Donati MB, Lorenzet R. Coagulation factors and tumor cell biology: the role of tissue factor. Pathophysiol Haemost Thromb. 2003;33(Suppl. 1):22–25
  54. Donati MB, Falanga A, Lorenzet R. Cancer and thrombosis: a two way interaction. In: Thrombosis. Fundamental and clinical aspects. Leuven University Press; 2003;p. 417–431
  55. Napoleone E, Zurlo F, Latella MC, et al. Paclitaxel downregulates tissue factor in cancer and host tumour-associated cells. Eur J Cancer. 2008 Nov 27;[Epub ahead of print]

PII: S1521-6926(09)00006-1

doi: 10.1016/j.beha.2009.01.005

Best Practice & Research Clinical Haematology
Volume 22, Issue 1 , Pages 3-8 , March 2009

Article Tools